BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant SP Europe, submitted on 07 January 1998 an application for Marketing Authorisation to 
the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for  Integrilin  solution  for 
infusion 0.75 mg/ml and for Integrilin solution for injection 2 mg/ml. After agreement by the CPMP 
on 22 November 1995, this medicinal product is referred to Part B of the Annex to Council Regulation 
No (EC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP  were: 
Rapporteur: 
Dr E. Abadie 
Co-Rapporteur:  
Prof. G. Vicari 
Licensing status: 
The product was licensed in Switzerland (PTCA indication) on 27 February 1997. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 29 January 1998. 
The Rapporteur's first assessment report was circulated to all CPMP Members on 15 April 1998. 
The Co-Rapporteur’s first assessment report was circulated to all CPMP Members on 15 April 
1998. 
During the meeting on 27 May 1998 the CPMP agreed on the consolidated list of questions to 
be sent to the applicant. The final consolidated list of questions was sent to the applicant on 28 
May 1998.  
The applicant submitted the responses to the consolidated list of questions on 02 October 1998. 
The  Rapporteur/Co-Rapporteur  circulated  the  joint  assessment  report  on  the  applicant’s 
responses to the list of questions to all CPMP Members on 23 November 1998. 
List of outstanding issues was adopted at the CPMP meting on 15 December 1998. 
The applicant requested on 11 January 1999 a postponement of the oral explanation scheduled 
for the January 1999 CPMP meeting. 
The  applicant  submitted  a  draft  response  to  the  list  of  outstanding  issues  to  the  EMEA  on  
25  January  1999.  The  final  response  on  the  list  of  outstanding  issues  was  submitted  by  the 
applicant on 01 February 1999. 
The applicant gave an oral presentation on 23 February 1999 during the CPMP meeting and the 
remaining issues were presented. 
The  CPMP  in  the  light  of  the  overall  data  submitted  and  the  scientific  discussion  within  the 
committee  issued  a  positive  opinion  for  granting  a  Marketing  Authorisation  to  Integrilin  on  
25 February 1999. 
The  Commission  services  submitted  the  draft  decision  concerning  Integrilin  to  the  Standing 
Committee  on  Medicinal  products  for  human  use,  on  the  09  April  1999.  Written  observation 
was  received  within  the  written  procedure  laid  down  by  Article  3  of  Commission  Regulation 
(EC) No. 1662/95 of 7 July 1995.  Since the written observation raised a question of scientific 
and technical nature, the procedure was suspended. 
On 10 May 1999 in accordance with Article 10 (3) of Council Regulation (EEC) No 2309/93, 
the European Commission requested the CPMP to consider a question of scientific and technical 
nature  on  the  wording  of  section  4.1  of  the  SPC  (Therapeutic  indication)  by  replacing 
“Integrilin is indicated for the prevention of early new myocardial infarction” with “Integrilin is 
indicated for the prevention of early myocardial infarction”. 
1/2 
EMEA 2004 
 
 
• 
• 
• 
During  its  meeting  of  18-20  May  1999  the  CPMP  considered  the  European  Commission’s 
request and sent a letter of reply dated 20 May 1999 to inform the European Commission of the 
outcome of their discussions concerning the issue raised in the letter of 10 May 1999. 
The  services  of  the  Commission  informed  the  members  of  the  Standing  Committee  on 
Medicinal Products for human use of the outcome of the CPMP discussions on the 02 June 1999 
and requested final opinions by written procedure by 02 July 1999. 
The  CPMP  Opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 1 July 1999. 
2/2 
EMEA 2004 
 
 
 
